

Haematologica  
HAEMATOL/2019/229161  
Version 3

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1

Eugen Tausch, Philipp Beck, Richard F. Schlenk, Billy J. Jebaraj, Anna Dolnik, Deyan Y. Yosifov, Peter Hillmen, Fritz Offner, Ann Janssens, K. Govind Babu, Sebastian Grosicki, Jiri Mayer, Panagiotis Panagiotidis, Astrid McKeown, Ira V. Gupta, Alexandra Skorupa, Celine Pallaud, Lars Bullinger, Daniel Mertens, Hartmut Döhner, and Stephan Stilgenbauer

Disclosures: Disclosures: ET and SS report research support from Novartis; AS and CP are employees of Novartis; IG is an employee of GSK; AM is an employee of AstraZeneca and has stock ownership of GSK, Novartis and AstraZeneca; AS has stock ownership of Novartis; AJ reports consultancy, speakers bureau, board membership and travel support of Janssen, Roche, Abbvie, Sanofi, Amgen, Novartis and Mundipharma; PP reports consultancy, research funding, honoraria and board membership of Genesis, Roche, Abbvie, Novartis, Takeda, Janssen and Sandoz; PH reports honoraria, speakers bureau, research funding and travel support from Janssen, Abbvie, Gilead, Pharmacyclics and Roche; JM reports research support from GSK; PB, RS, BJ, AD, DY, FO, LB, DM and HD have no conflicts of interest.

Contributions: ET and SS designed the research; ET, PB, BJ, AD and DY performed laboratory analyses; ET, RS and AM performed statistical analyses, all authors interpreted the data; ET and SS wrote the first draft of the manuscript and all authors contributed to and approved the manuscript.